Exenatide dosage: reported doses and schedule
An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
Also called: Byetta, Bydureon, Bydureon BCise, exendin-4, AC2993, ITCA 650.
GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.
Typical reported dose: 5 mcg twice a day, then 10 mcg if needed
- Immediate release: 5 then 10 mcg twice daily: 5 mcg twice daily for 1 month, then 10 mcg twice daily if needed after 1 month twice daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes. (source)
- Historical weekly depot: 2 mg: 2 mg once weekly once weekly, under the skin. Drug label. Studied in: Weekly exenatide diabetes label; BCise included adults and ages 10+. (source)
- Dose finding: 2.5 mcg twice daily: 2.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
- Dose finding: 5 mcg twice daily: 5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
- Dose finding: 7.5 mcg twice daily: 7.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
- Dose finding: 10 mcg twice daily: 10 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Exenatide
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
Sources
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026, 2026
- Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications, 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study., Keshen A et al. · World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
- DailyMed - EXENATIDE injection, 2026
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases, 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- TRULICITY, 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- DailyMed - BYDUREON BCISE- exenatide injection, suspension, extended release, 2025
- Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society., Mozaffarian D et al. · Obesity pillars · 2025
- Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications, 2025
- 2024 First Generic Drug Approvals, 2024
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.